New: Clinical trial search, funded by the National Cancer InstituteNew: NCI-funded clinical trial search

How do you manage brain fog from CML tyrosine kinase inhibitors?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

How does the CLL17 trial presented at ASH 2025 change current practice guidelines?

In a patient who has been receiving 1L Ibrutinib for TP53+ CLL for years with complete hematologic response but detectable MRD, is there any role to switch to the novel BTKi agents given better PFS?

What is your preferred 1L treatment for newly diagnosed Del(17p)/TP53 mutation, high-risk CLL?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 24 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
TrialMatch
Mobile App

Company

About
Careers
Events
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.